Global Pets Anti-infectives Market Size By Type (Injection, Unguent), By Application (Dogs, Cats), By Region, And Segment Forecasts, 2023 to 2032

The Global Pets Anti-infectives Market was valued at USD 4.3 billion in 2023 and is projected to surpass USD 7.6 billion by 2031, growing at a CAGR of 7.3% during the forecast period from 2023 to 2031. This growth is driven by the increasing prevalence of infectious diseases among companion animals, growing pet ownership globally, and heightened awareness among pet parents regarding preventive healthcare. Rising expenditures on veterinary services and the surge in demand for effective, fast-acting anti-infective medications—including antibiotics, antifungals, and antivirals—are also contributing to the market’s expansion.

Drivers:

1. Rising Pet Ownership and Spending on Veterinary Care

The global increase in pet ownership, especially in urban areas, has led to higher spending on pet health and wellness. Companion animals are increasingly viewed as family members, driving demand for premium healthcare products such as anti-infectives.

2. Surge in Zoonotic and Infectious Diseases

Infectious diseases like leptospirosis, kennel cough, and feline upper respiratory tract infections are driving demand for effective treatments. Growing concerns over zoonotic transmission have further intensified focus on timely veterinary intervention.

3. Advancements in Veterinary Pharmaceuticals

Innovation in drug formulations, such as long-acting injectables, flavored chewables, and easy-to-administer topical treatments, are boosting compliance and driving market growth.

Restraints:

1. Stringent Regulatory Approvals

Veterinary anti-infectives face lengthy and complex approval processes, especially for new drugs. These regulations vary across regions, creating barriers for market entry and expansion.

2. Antimicrobial Resistance (AMR)

Overuse and misuse of antibiotics in pets contribute to rising antimicrobial resistance, prompting regulatory bodies to impose restrictions. This may hinder the unrestricted growth of antibiotic-based treatments in the future.

Opportunity:

1. Growth of E-commerce in Veterinary Products

The rising trend of online pet pharmacies and telehealth platforms is making anti-infective medications more accessible to pet owners, especially in remote areas.

2. Increasing Demand in Emerging Economies

Rapid urbanization, rising disposable incomes, and growing awareness about pet health in emerging markets such as India, Brazil, and Southeast Asia present substantial growth potential.

Market by System Type Insights:

By type, Antibiotics held the largest share of the market in 2023, owing to their widespread use in treating bacterial infections in pets. However, the antivirals segment is expected to witness the fastest growth during the forecast period, driven by rising incidences of viral infections in both cats and dogs and the development of novel antiviral compounds.

Market by End-use Insights:

Veterinary Hospitals and Clinics dominated the market in 2023, accounting for over 50% of global revenue. These establishments offer comprehensive diagnostic and treatment services, making them the preferred choice for pet owners seeking reliable care. Meanwhile, online pharmacies are emerging as a rapidly growing distribution channel, especially for repeat prescriptions.

Market by Regional Insights:

North America led the global pets anti-infectives market in 2023 due to high pet ownership rates, advanced veterinary healthcare infrastructure, and strong presence of major pharmaceutical firms. Asia-Pacific is anticipated to grow at the fastest rate through 2031, bolstered by rising pet adoption, increasing income levels, and expanding awareness regarding animal healthcare.

Competitive Scenario:

Key market players include Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim, Merck Animal Health, Vetoquinol S.A., Ceva Santé Animale, Bayer AG, Virbac, Norbrook Laboratories, and Dechra Pharmaceuticals. These companies focus on R&D, strategic collaborations, and global expansion to gain a competitive edge.

Scope of Work – Global Pets Anti-infectives Market

Report Metric Details

Market Size (2023) USD 4.3 billion

Projected Market Size (2031) USD 7.6 billion

CAGR (2023–2031) 7.3%

Market Segments By Product Type (Antibiotics, Antivirals, Antifungals), By End-use (Veterinary Hospitals, Clinics, Online Pharmacies), By Region

Growth Drivers Rising pet ownership, increase in infectious diseases, innovation in veterinary medicine

Opportunities Expansion in emerging markets, rise of e-commerce, development of resistance-free formulations

Key Market Developments:

2023: Zoetis introduced a next-generation injectable antibiotic with extended-release properties, reducing treatment frequency for bacterial infections.

2024: Elanco Animal Health launched a new range of oral antivirals specifically targeting common feline viral infections.

2025: Boehringer Ingelheim collaborated with a leading telehealth platform to deliver anti-infective solutions directly through veterinary e-prescriptions.

FAQs:

1. What is the current market size of the Global Pets Anti-infectives Market?

The market size was USD 4.3 billion in 2023.

2. What is the major growth driver of the Global Pets Anti-infectives Market?

The market is driven by rising pet ownership, increasing incidences of infectious diseases, and innovation in veterinary treatments.

3. Which is the largest region during the forecast period in the Global Pets Anti-infectives Market?

North America held the largest market share in 2023.

4. Which segment accounted for the largest market share in the Global Pets Anti-infectives Market?

The Antibiotics segment accounted for the largest share in 2023.

5. Who are the key market players in the Global Pets Anti-infectives Market?

Major players include Zoetis, Elanco, Boehringer Ingelheim, Merck Animal Health, and Ceva Santé Animale.